News
NICE recommends rucaparib for use on Cancer Drugs Fund
The National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through...
US approval for Lilly’s migraine treatment Reyvow
The FDA has approved Eli Lilly’s Reyvow (lasmiditan), the first and only medicine in a new class of acute treatment for migraine.
As with other...
Shionogi & Hsiri collaborate of treating mycobacterial diseases
Japan’s Shionogi has entered into a new license agreement and research collaboration with US biopharma Hsiri Therapeutics to discover and develop additional novel therapeutics...
